|
Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome. |
|
Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome.
Dig Dis Sci. 2007 Oct 16
Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
Department
of Internal Medicine and Systemic Diseases, Liver Operative Unit,
Catania University Polyclinic, Via S. Sofia 86 (edificio 29. I piano),
Catania, 95123, Italy,
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
Purpose: Hepatorenal
syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in
cirrhotic patients presenting ascites. We investigated the improvement
of renal function in subjects with hepatorenal syndrome after
terlipressin administration and the survival times after this
treatment.
Fifty-two patients affected by cirrhosis, with diagnosis of
hepatorenal syndrome were treated with intravenous terlipressin plus
albumin (group A) or with albumin alone (group B). Liver and renal
function, plasma renin activity, and aldosterone plasma levels were
monitored. Results: Patients from group A showed a significant
improvement (p < 0.001) of renal function valued by creatinine rate
compared with the results obtained in group B. The probability of
survival was higher in the group A (p < 0.0001). Conclusions: Our
results seem to confirm that the administration of terlipressin plus
albumin improves renal function in patients with cirrhosis and type I
HRS and that a reversal of hepatorenal syndrome is strongly associated
with improved survival.
|
